DE-127 Ophthalmic Solution low dose + DE-127 Ophthalmic Solution medium dose + DE-127 Ophthalmic Solution high dose + Placebo Ophthalmic Solution
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout DE-127 Ophthalmic Solution low dose + DE-127 Ophthalmic Solution medium dose + DE-127 Ophthalmic Solution high dose + Placebo Ophthalmic Solution
DE-127 Ophthalmic Solution low dose + DE-127 Ophthalmic Solution medium dose + DE-127 Ophthalmic Solution high dose + Placebo Ophthalmic Solution is a phase 2 stage product being developed by Santen Pharmaceutical for Myopia. The current trial status is completed. This product is registered under clinical trial identifier NCT03329638. Target conditions include Myopia.
What happened to similar drugs?
0 of 5 similar drugs in Myopia were approved
Approved (0) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03329638 | Phase 2 | Completed |
Competing Products
5 competing products in Myopia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 40 |
| Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT | Novartis | Phase 3 | 40 |
| Ranibizumab | Novartis | Phase 3 | 40 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 44 |
| VEGF Trap-Eye (BAY86-5321) | Regeneron Pharmaceuticals | Phase 3 | 40 |